Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute ...

A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...

Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a chemical imaging probe ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy.

A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...

Medication burden, characterized by polypharmacy and suboptimal treatment adherence, is a predictor for acute care use among ...

The FDA approved darolutamide for mHSPC on June 3, [2025], so we now have this in our armamentarium, along with all the other ...

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate ...

The investigational drug BMS-986365 may help patients with mCRPC previously treated with ARPIs overcome drug resistance, despite their genomic status. The investigational dual androgen receptor ...

Efficacy data remain consistent with prior disclosure and continue to demonstrate broad and deep PSA responses, with 55% PSA50 response rate and ...